The OncoAlert Network 🚨
@oncoalert.bsky.social
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨
www.OncoAlert360.com
www.OncoAlert360.com
Pinned
Colleagues, the Complete #ESMO25 OncoAlert Newsletter is coming Oct 27‼️ GET IT HERE👉 oncoalert.m-pages.com/nhMpwe/oncoa...
50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social
50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social
IKCS Europe 2026🌍Transforming #KidneyCancer Research👉 buff.ly/WgG7n4V
Join the International Kidney Cancer Symposium (IKCS): Europe in Paris, France🇫🇷 bringing together global leaders in #KidneyCancer to explore cutting-edge research, clinical innovation, and future directions in care.
Join the International Kidney Cancer Symposium (IKCS): Europe in Paris, France🇫🇷 bringing together global leaders in #KidneyCancer to explore cutting-edge research, clinical innovation, and future directions in care.
February 17, 2026 at 1:47 PM
IKCS Europe 2026🌍Transforming #KidneyCancer Research👉 buff.ly/WgG7n4V
Join the International Kidney Cancer Symposium (IKCS): Europe in Paris, France🇫🇷 bringing together global leaders in #KidneyCancer to explore cutting-edge research, clinical innovation, and future directions in care.
Join the International Kidney Cancer Symposium (IKCS): Europe in Paris, France🇫🇷 bringing together global leaders in #KidneyCancer to explore cutting-edge research, clinical innovation, and future directions in care.
20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment
www.annalsofoncology.org/article/S092...
20 years after approval, trastuzumab remains the therapeutic backbone for HER2+ early #BreastCancer delivering durable survival benefits across risk groups and chemo regimens
www.annalsofoncology.org/article/S092...
20 years after approval, trastuzumab remains the therapeutic backbone for HER2+ early #BreastCancer delivering durable survival benefits across risk groups and chemo regimens
February 17, 2026 at 1:34 PM
20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment
www.annalsofoncology.org/article/S092...
20 years after approval, trastuzumab remains the therapeutic backbone for HER2+ early #BreastCancer delivering durable survival benefits across risk groups and chemo regimens
www.annalsofoncology.org/article/S092...
20 years after approval, trastuzumab remains the therapeutic backbone for HER2+ early #BreastCancer delivering durable survival benefits across risk groups and chemo regimens
OncoAlert🚨 #AUC3 Week 2026
Their Publication is NOW OUT
ARTICLE HERE: 👉 buff.ly/bAgkPQC
Presenter Dr. Michael Atkins🇺🇸
Adjuvant Therapy Debate in #KidneyCancer : PRO
Their Publication is NOW OUT
ARTICLE HERE: 👉 buff.ly/bAgkPQC
Presenter Dr. Michael Atkins🇺🇸
Adjuvant Therapy Debate in #KidneyCancer : PRO
February 17, 2026 at 12:32 PM
OncoAlert🚨 #AUC3 Week 2026
Their Publication is NOW OUT
ARTICLE HERE: 👉 buff.ly/bAgkPQC
Presenter Dr. Michael Atkins🇺🇸
Adjuvant Therapy Debate in #KidneyCancer : PRO
Their Publication is NOW OUT
ARTICLE HERE: 👉 buff.ly/bAgkPQC
Presenter Dr. Michael Atkins🇺🇸
Adjuvant Therapy Debate in #KidneyCancer : PRO
NOW FREE & ON DEMAND‼️
The 6th Annual OncoAlert Colloquium 🚨
REGISTER👉 buff.ly/UDfpkP8
THE YEAR IN REVIEW IN ONCOLOGY
As ALWAYS ✅Patients Included
The 6th Annual OncoAlert Colloquium 🚨
REGISTER👉 buff.ly/UDfpkP8
THE YEAR IN REVIEW IN ONCOLOGY
As ALWAYS ✅Patients Included
February 17, 2026 at 9:50 AM
NOW FREE & ON DEMAND‼️
The 6th Annual OncoAlert Colloquium 🚨
REGISTER👉 buff.ly/UDfpkP8
THE YEAR IN REVIEW IN ONCOLOGY
As ALWAYS ✅Patients Included
The 6th Annual OncoAlert Colloquium 🚨
REGISTER👉 buff.ly/UDfpkP8
THE YEAR IN REVIEW IN ONCOLOGY
As ALWAYS ✅Patients Included
A reminder that #APCCC26 🇨🇭is coming in 2026
This is a Conference is OPEN TO EVERYONE, not just the Panel members and EARLY
👉️ REGISTER HERE: buff.ly/P3pK7TA
Only 🔟 days left until the Early Bird deadline (28 February 2026)
Enjoy 20% off when registering APCCC & IPCS 2026
This is a Conference is OPEN TO EVERYONE, not just the Panel members and EARLY
👉️ REGISTER HERE: buff.ly/P3pK7TA
Only 🔟 days left until the Early Bird deadline (28 February 2026)
Enjoy 20% off when registering APCCC & IPCS 2026
February 17, 2026 at 7:17 AM
A reminder that #APCCC26 🇨🇭is coming in 2026
This is a Conference is OPEN TO EVERYONE, not just the Panel members and EARLY
👉️ REGISTER HERE: buff.ly/P3pK7TA
Only 🔟 days left until the Early Bird deadline (28 February 2026)
Enjoy 20% off when registering APCCC & IPCS 2026
This is a Conference is OPEN TO EVERYONE, not just the Panel members and EARLY
👉️ REGISTER HERE: buff.ly/P3pK7TA
Only 🔟 days left until the Early Bird deadline (28 February 2026)
Enjoy 20% off when registering APCCC & IPCS 2026
OncoAlert🚨The #AUC3 WEEK 2026
Their Publication is NOW OUTARTICLE HERE: 👉 buff.ly/bAgkPQC
Presenter Dr. Brian Rini 🇺🇸
(Adjuvant Therapy Debate) CON in #KidneyCancer RCC
Their Publication is NOW OUTARTICLE HERE: 👉 buff.ly/bAgkPQC
Presenter Dr. Brian Rini 🇺🇸
(Adjuvant Therapy Debate) CON in #KidneyCancer RCC
February 16, 2026 at 5:15 PM
OncoAlert🚨The #AUC3 WEEK 2026
Their Publication is NOW OUTARTICLE HERE: 👉 buff.ly/bAgkPQC
Presenter Dr. Brian Rini 🇺🇸
(Adjuvant Therapy Debate) CON in #KidneyCancer RCC
Their Publication is NOW OUTARTICLE HERE: 👉 buff.ly/bAgkPQC
Presenter Dr. Brian Rini 🇺🇸
(Adjuvant Therapy Debate) CON in #KidneyCancer RCC
The #OncoAlertColloquium 2026 Breast Malignancies🚨 DAY TWO
Presentation by Dr. Matteo Lambertini 🇮🇹 : ER+ Early #BreastCancer
REGISTER HERE TO WATCH: buff.ly/FaS5Cb6
ER+ Early #BreastCancer — What changed in clinical practice in 2025 📊
Presentation by Dr. Matteo Lambertini 🇮🇹 : ER+ Early #BreastCancer
REGISTER HERE TO WATCH: buff.ly/FaS5Cb6
ER+ Early #BreastCancer — What changed in clinical practice in 2025 📊
February 16, 2026 at 2:43 PM
The #OncoAlertColloquium 2026 Breast Malignancies🚨 DAY TWO
Presentation by Dr. Matteo Lambertini 🇮🇹 : ER+ Early #BreastCancer
REGISTER HERE TO WATCH: buff.ly/FaS5Cb6
ER+ Early #BreastCancer — What changed in clinical practice in 2025 📊
Presentation by Dr. Matteo Lambertini 🇮🇹 : ER+ Early #BreastCancer
REGISTER HERE TO WATCH: buff.ly/FaS5Cb6
ER+ Early #BreastCancer — What changed in clinical practice in 2025 📊
OncoAlert🚨The #AUC3 WEEK 2026
Their Publication is NOW OUTARTICLE HERE: 👉 buff.ly/bAgkPQC
Presenter: Cristina Suarez 🇪🇸 Treatment Strategy for Very Favorable and Favorable Risk Disease #kidneyCancer
Their Publication is NOW OUTARTICLE HERE: 👉 buff.ly/bAgkPQC
Presenter: Cristina Suarez 🇪🇸 Treatment Strategy for Very Favorable and Favorable Risk Disease #kidneyCancer
February 16, 2026 at 11:08 AM
OncoAlert🚨The #AUC3 WEEK 2026
Their Publication is NOW OUTARTICLE HERE: 👉 buff.ly/bAgkPQC
Presenter: Cristina Suarez 🇪🇸 Treatment Strategy for Very Favorable and Favorable Risk Disease #kidneyCancer
Their Publication is NOW OUTARTICLE HERE: 👉 buff.ly/bAgkPQC
Presenter: Cristina Suarez 🇪🇸 Treatment Strategy for Very Favorable and Favorable Risk Disease #kidneyCancer
🌍 You’re invited to the 2026 International Prostate Cancer Symposium (IPCS)
📅 April 28–29, 2026 | 📍 Lugano, Switzerland @IPCSymposium
REGISTRATION 👉 buff.ly/9hvqRn0...
Join global leaders in prostate cancer research and care to explore next-generation therapies and precision strategies
📅 April 28–29, 2026 | 📍 Lugano, Switzerland @IPCSymposium
REGISTRATION 👉 buff.ly/9hvqRn0...
Join global leaders in prostate cancer research and care to explore next-generation therapies and precision strategies
February 16, 2026 at 10:37 AM
🌍 You’re invited to the 2026 International Prostate Cancer Symposium (IPCS)
📅 April 28–29, 2026 | 📍 Lugano, Switzerland @IPCSymposium
REGISTRATION 👉 buff.ly/9hvqRn0...
Join global leaders in prostate cancer research and care to explore next-generation therapies and precision strategies
📅 April 28–29, 2026 | 📍 Lugano, Switzerland @IPCSymposium
REGISTRATION 👉 buff.ly/9hvqRn0...
Join global leaders in prostate cancer research and care to explore next-generation therapies and precision strategies
The #OncoAlertColloquium 2026 GYN Malignancies🚨 DAY FOUR (ESGO)
Presentation by Dr. Christina Fotopoulou🇬🇧 : Year in Review Surgical #VaginalCancer
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
We are very pleased to present the latest developments in Surgical vaginal cancer diagnosis, management
Presentation by Dr. Christina Fotopoulou🇬🇧 : Year in Review Surgical #VaginalCancer
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
We are very pleased to present the latest developments in Surgical vaginal cancer diagnosis, management
February 13, 2026 at 4:28 PM
The #OncoAlertColloquium 2026 GYN Malignancies🚨 DAY FOUR (ESGO)
Presentation by Dr. Christina Fotopoulou🇬🇧 : Year in Review Surgical #VaginalCancer
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
We are very pleased to present the latest developments in Surgical vaginal cancer diagnosis, management
Presentation by Dr. Christina Fotopoulou🇬🇧 : Year in Review Surgical #VaginalCancer
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
We are very pleased to present the latest developments in Surgical vaginal cancer diagnosis, management
oin us at the 30th Annual International Congress on Hematologic Malignancies (HYBRID): Focus on Leukemias, Lymphomas & Myeloma.
HCP's Register FOR 50% off 👉 (USE CODE: ONCOALERT ) tinyurl.com/5n7fmpcy
Engage with internationally renowned experts through case-based discussions and updates
HCP's Register FOR 50% off 👉 (USE CODE: ONCOALERT ) tinyurl.com/5n7fmpcy
Engage with internationally renowned experts through case-based discussions and updates
February 13, 2026 at 2:25 PM
oin us at the 30th Annual International Congress on Hematologic Malignancies (HYBRID): Focus on Leukemias, Lymphomas & Myeloma.
HCP's Register FOR 50% off 👉 (USE CODE: ONCOALERT ) tinyurl.com/5n7fmpcy
Engage with internationally renowned experts through case-based discussions and updates
HCP's Register FOR 50% off 👉 (USE CODE: ONCOALERT ) tinyurl.com/5n7fmpcy
Engage with internationally renowned experts through case-based discussions and updates
JOIN COR2ED and Dr. Tolaney for Managing ADC Tox in HER2+ mBreast Cancer
👉 cor2ed.com/adc-toxiciti...
Nausea and vomiting are among the most common adverse events associated with ADCs, particularly T-DXd, for patients with HER2-positive metastatic breast cancer.
👉 cor2ed.com/adc-toxiciti...
Nausea and vomiting are among the most common adverse events associated with ADCs, particularly T-DXd, for patients with HER2-positive metastatic breast cancer.
February 13, 2026 at 9:30 AM
JOIN COR2ED and Dr. Tolaney for Managing ADC Tox in HER2+ mBreast Cancer
👉 cor2ed.com/adc-toxiciti...
Nausea and vomiting are among the most common adverse events associated with ADCs, particularly T-DXd, for patients with HER2-positive metastatic breast cancer.
👉 cor2ed.com/adc-toxiciti...
Nausea and vomiting are among the most common adverse events associated with ADCs, particularly T-DXd, for patients with HER2-positive metastatic breast cancer.
The #OncoAlertColloquium 2026 GU Malignancies🚨 DAY ONE
Presentation by Dr. Tom Powles: Year in Review in #BladderCancer
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Tom Powles 2025 year-in-review highlights real progress—and ongoing challenges—in Bladder Cancer
Presentation by Dr. Tom Powles: Year in Review in #BladderCancer
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Tom Powles 2025 year-in-review highlights real progress—and ongoing challenges—in Bladder Cancer
February 12, 2026 at 11:56 AM
The #OncoAlertColloquium 2026 GU Malignancies🚨 DAY ONE
Presentation by Dr. Tom Powles: Year in Review in #BladderCancer
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Tom Powles 2025 year-in-review highlights real progress—and ongoing challenges—in Bladder Cancer
Presentation by Dr. Tom Powles: Year in Review in #BladderCancer
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Tom Powles 2025 year-in-review highlights real progress—and ongoing challenges—in Bladder Cancer
A Great Day for the OncoAlert Community, 10,000 Followers on Instagram!!!
Huge thanks to all who follow us and engage with OncoAlert 🚨 and a warm invite to follow us on Instagram at www.instagram.com/oncoalert/
As always WE ARE ALL ONCOALERT🌐 For Colleagues...By Colleagues
Huge thanks to all who follow us and engage with OncoAlert 🚨 and a warm invite to follow us on Instagram at www.instagram.com/oncoalert/
As always WE ARE ALL ONCOALERT🌐 For Colleagues...By Colleagues
February 12, 2026 at 10:30 AM
A Great Day for the OncoAlert Community, 10,000 Followers on Instagram!!!
Huge thanks to all who follow us and engage with OncoAlert 🚨 and a warm invite to follow us on Instagram at www.instagram.com/oncoalert/
As always WE ARE ALL ONCOALERT🌐 For Colleagues...By Colleagues
Huge thanks to all who follow us and engage with OncoAlert 🚨 and a warm invite to follow us on Instagram at www.instagram.com/oncoalert/
As always WE ARE ALL ONCOALERT🌐 For Colleagues...By Colleagues
🌍 You’re invited to the 2026 International Prostate Cancer Symposium (IPCS)
📅 April 28–29, 2026 | 📍 Lugano, Switzerland @IPCSymposium
REGISTRATION 👉 buff.ly/9hvqRn0...
Join global leaders in prostate cancer research and care to explore next-generation therapies and precision strategies
📅 April 28–29, 2026 | 📍 Lugano, Switzerland @IPCSymposium
REGISTRATION 👉 buff.ly/9hvqRn0...
Join global leaders in prostate cancer research and care to explore next-generation therapies and precision strategies
February 11, 2026 at 2:17 PM
🌍 You’re invited to the 2026 International Prostate Cancer Symposium (IPCS)
📅 April 28–29, 2026 | 📍 Lugano, Switzerland @IPCSymposium
REGISTRATION 👉 buff.ly/9hvqRn0...
Join global leaders in prostate cancer research and care to explore next-generation therapies and precision strategies
📅 April 28–29, 2026 | 📍 Lugano, Switzerland @IPCSymposium
REGISTRATION 👉 buff.ly/9hvqRn0...
Join global leaders in prostate cancer research and care to explore next-generation therapies and precision strategies
The #OncoAlertColloquium 2026 GYN Malignancies🚨 DAY FOUR (ESGO)
Presentation by Dr. Isabelle Ray-Coquard 🇫🇷 : Year in Review Medical #OvarianCancer
REGISTER HERE TO WATCH: buff.ly/xwD5G2D
In 2025, the standard 1L maintenance strategy in ovarian cancer remains unchanged:
Presentation by Dr. Isabelle Ray-Coquard 🇫🇷 : Year in Review Medical #OvarianCancer
REGISTER HERE TO WATCH: buff.ly/xwD5G2D
In 2025, the standard 1L maintenance strategy in ovarian cancer remains unchanged:
February 11, 2026 at 11:38 AM
The #OncoAlertColloquium 2026 GYN Malignancies🚨 DAY FOUR (ESGO)
Presentation by Dr. Isabelle Ray-Coquard 🇫🇷 : Year in Review Medical #OvarianCancer
REGISTER HERE TO WATCH: buff.ly/xwD5G2D
In 2025, the standard 1L maintenance strategy in ovarian cancer remains unchanged:
Presentation by Dr. Isabelle Ray-Coquard 🇫🇷 : Year in Review Medical #OvarianCancer
REGISTER HERE TO WATCH: buff.ly/xwD5G2D
In 2025, the standard 1L maintenance strategy in ovarian cancer remains unchanged:
Join us at the 43rd Annual Miami Breast Cancer Meeting by our Collaborators from PER
REGISTER HERE 👉 tinyurl.com/3cmfj2a5
HCP's Register FOR 50% off 🚨 (USE CODE: ONCOALERT)
Here is Dr. Hope Rugo to tell us more 43rd Annual Miami Breast Miami Florida March 5-8 ,2026
REGISTER HERE 👉 tinyurl.com/3cmfj2a5
HCP's Register FOR 50% off 🚨 (USE CODE: ONCOALERT)
Here is Dr. Hope Rugo to tell us more 43rd Annual Miami Breast Miami Florida March 5-8 ,2026
February 11, 2026 at 11:26 AM
Join us at the 43rd Annual Miami Breast Cancer Meeting by our Collaborators from PER
REGISTER HERE 👉 tinyurl.com/3cmfj2a5
HCP's Register FOR 50% off 🚨 (USE CODE: ONCOALERT)
Here is Dr. Hope Rugo to tell us more 43rd Annual Miami Breast Miami Florida March 5-8 ,2026
REGISTER HERE 👉 tinyurl.com/3cmfj2a5
HCP's Register FOR 50% off 🚨 (USE CODE: ONCOALERT)
Here is Dr. Hope Rugo to tell us more 43rd Annual Miami Breast Miami Florida March 5-8 ,2026
FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
www.fda.gov/drugs/resour...
On February 10, 2026, FDA approved pembrolizumab, alone or with berahyaluronidase alfa-pmph, plus paclitaxel, w/ or w/o bevacizumab
www.fda.gov/drugs/resour...
On February 10, 2026, FDA approved pembrolizumab, alone or with berahyaluronidase alfa-pmph, plus paclitaxel, w/ or w/o bevacizumab
February 11, 2026 at 8:35 AM
FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
www.fda.gov/drugs/resour...
On February 10, 2026, FDA approved pembrolizumab, alone or with berahyaluronidase alfa-pmph, plus paclitaxel, w/ or w/o bevacizumab
www.fda.gov/drugs/resour...
On February 10, 2026, FDA approved pembrolizumab, alone or with berahyaluronidase alfa-pmph, plus paclitaxel, w/ or w/o bevacizumab
The #OncoAlertColloquium 2026 GI Malignancies🚨 DAY THREE
Presentation by Dr. Nicholas Hornstein🇺🇸 of Northwest Health: Year in Review Upper GI
REGISTER HERE TO WATCH: buff.ly/FaS5Cb6
🚨 Practice-changing science in 2025: Upper GI Oncology 🚨
Presentation by Dr. Nicholas Hornstein🇺🇸 of Northwest Health: Year in Review Upper GI
REGISTER HERE TO WATCH: buff.ly/FaS5Cb6
🚨 Practice-changing science in 2025: Upper GI Oncology 🚨
February 10, 2026 at 1:12 PM
The #OncoAlertColloquium 2026 GI Malignancies🚨 DAY THREE
Presentation by Dr. Nicholas Hornstein🇺🇸 of Northwest Health: Year in Review Upper GI
REGISTER HERE TO WATCH: buff.ly/FaS5Cb6
🚨 Practice-changing science in 2025: Upper GI Oncology 🚨
Presentation by Dr. Nicholas Hornstein🇺🇸 of Northwest Health: Year in Review Upper GI
REGISTER HERE TO WATCH: buff.ly/FaS5Cb6
🚨 Practice-changing science in 2025: Upper GI Oncology 🚨
The #OncoAlertColloquium 2026 Breast Malignancies🚨 DAY TWO
Presentation by Dr. Hope Rugo🇺🇸 of City of Hope: Adv TNBC #BreastCancer
REGISTER HERE TO WATCH: buff.ly/OhocR7D
Presentation by Dr. Hope Rugo🇺🇸 of City of Hope: Adv TNBC #BreastCancer
REGISTER HERE TO WATCH: buff.ly/OhocR7D
February 9, 2026 at 4:00 PM
The #OncoAlertColloquium 2026 Breast Malignancies🚨 DAY TWO
Presentation by Dr. Hope Rugo🇺🇸 of City of Hope: Adv TNBC #BreastCancer
REGISTER HERE TO WATCH: buff.ly/OhocR7D
Presentation by Dr. Hope Rugo🇺🇸 of City of Hope: Adv TNBC #BreastCancer
REGISTER HERE TO WATCH: buff.ly/OhocR7D
Join us at the 43rd Annual Miami Breast Cancer Meeting by our Collaborators from PER
tinyurl.com/3cmfj2a5 ⭐️ HCP's Register FOR 50% off 👉 (USE CODE: ONCOALERT)
Here is Dr. Patrick Borgen to tell us more 43rd Annual Miami Breast Miami Florida March 5-8 ,2026
tinyurl.com/3cmfj2a5 ⭐️ HCP's Register FOR 50% off 👉 (USE CODE: ONCOALERT)
Here is Dr. Patrick Borgen to tell us more 43rd Annual Miami Breast Miami Florida March 5-8 ,2026
February 8, 2026 at 12:54 PM
Join us at the 43rd Annual Miami Breast Cancer Meeting by our Collaborators from PER
tinyurl.com/3cmfj2a5 ⭐️ HCP's Register FOR 50% off 👉 (USE CODE: ONCOALERT)
Here is Dr. Patrick Borgen to tell us more 43rd Annual Miami Breast Miami Florida March 5-8 ,2026
tinyurl.com/3cmfj2a5 ⭐️ HCP's Register FOR 50% off 👉 (USE CODE: ONCOALERT)
Here is Dr. Patrick Borgen to tell us more 43rd Annual Miami Breast Miami Florida March 5-8 ,2026
The #OncoAlertColloquium 2026 Melanoma,Heme & GeriOnc🚨DAY 6
Presentation by Dr. Kristen Haase🇨🇦 : Geriatric Oncology Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Day 6 February 7, 2026 Melanoma, Heme & @SIOGorg Sessions
As ALWAYS ✅PATIENTS INCLUDED
Presentation by Dr. Kristen Haase🇨🇦 : Geriatric Oncology Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Day 6 February 7, 2026 Melanoma, Heme & @SIOGorg Sessions
As ALWAYS ✅PATIENTS INCLUDED
February 7, 2026 at 5:45 PM
The #OncoAlertColloquium 2026 Melanoma,Heme & GeriOnc🚨DAY 6
Presentation by Dr. Kristen Haase🇨🇦 : Geriatric Oncology Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Day 6 February 7, 2026 Melanoma, Heme & @SIOGorg Sessions
As ALWAYS ✅PATIENTS INCLUDED
Presentation by Dr. Kristen Haase🇨🇦 : Geriatric Oncology Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Day 6 February 7, 2026 Melanoma, Heme & @SIOGorg Sessions
As ALWAYS ✅PATIENTS INCLUDED
The #OncoAlertColloquium 2026 Melanoma,Heme & GeriOnc🚨DAY 6
Presentation by Dr. Al Ola Abdallah🇺🇸 : Multiple Myeloma Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Presentation by Dr. Al Ola Abdallah🇺🇸 : Multiple Myeloma Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
February 7, 2026 at 5:30 PM
The #OncoAlertColloquium 2026 Melanoma,Heme & GeriOnc🚨DAY 6
Presentation by Dr. Al Ola Abdallah🇺🇸 : Multiple Myeloma Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Presentation by Dr. Al Ola Abdallah🇺🇸 : Multiple Myeloma Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
The #OncoAlertColloquium 2026 🚨 DAY Six
Presentation by Dr. Fadi Haddad🇺🇸 : Leukemias Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Presentation by Dr. Fadi Haddad🇺🇸 : Leukemias Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
February 7, 2026 at 5:15 PM
The #OncoAlertColloquium 2026 🚨 DAY Six
Presentation by Dr. Fadi Haddad🇺🇸 : Leukemias Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Presentation by Dr. Fadi Haddad🇺🇸 : Leukemias Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
The #OncoAlertColloquium 2026 🚨 DAY Six
Presentation by Dr. Allison Betof 🇺🇸 : Melanoma Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Practice-changing melanoma data for 2025 👇
🔹 NADINA: Longer follow-up = growing strength of evidence for neoadjuvant ipi+nivo benefit
Presentation by Dr. Allison Betof 🇺🇸 : Melanoma Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Practice-changing melanoma data for 2025 👇
🔹 NADINA: Longer follow-up = growing strength of evidence for neoadjuvant ipi+nivo benefit
February 7, 2026 at 5:00 PM
The #OncoAlertColloquium 2026 🚨 DAY Six
Presentation by Dr. Allison Betof 🇺🇸 : Melanoma Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Practice-changing melanoma data for 2025 👇
🔹 NADINA: Longer follow-up = growing strength of evidence for neoadjuvant ipi+nivo benefit
Presentation by Dr. Allison Betof 🇺🇸 : Melanoma Year in Review
REGISTER HERE TO WATCH: buff.ly/pKfMiwK
Practice-changing melanoma data for 2025 👇
🔹 NADINA: Longer follow-up = growing strength of evidence for neoadjuvant ipi+nivo benefit